PredxBio

Access our brand new White Paper here

Menu

SpaceIQ Platform

An end-to-end decision intelligence platform that transforms spatial and multi-omic tissue data into explainable, decision-ready insights across drug discovery and clinical development.

SpaceIQ™ operationalizes tissue intelligence into decision-grade insight

SpaceIQ integrates unbiased spatial analytics with explainable AI to systematically characterize tissue organization, functional states, and molecular interactions across spatial imaging and multi-omic data. By modeling biology across cells, neighborhoods, and tissue regions, the platform reveals the mechanisms underlying response and resistance — in a form that teams can trust and act on.

–

Deployment model

PredxBio partners with teams through collaborative, knowledge-driven research engagements, with a clear and intentional pathway to secure, scalable, and modular software access. As insights mature from exploration to program dependency, SpaceIQ transitions from collaboration to platform licensing.

Cloud-Based Access
Rapid, secure access to SpaceIQ
with no infrastructure overhead
On-Premise Deployment
Fully controlled deployment within
customer-managed environments
Enterprise Integration
Scalable deployment with security,
compliance, and workflow integration

Core Capabilities of the SpaceIQ™ Platform

Step 1 — Data Ingestion & Integrity Assurance
The platform builds interpretable tissue-level models that link spatial patterns to underlying biological mechanisms, enabling experts to understand why response, resistance, or progression occurs.
Step 2 — Multi-Scale Tissue Modeling
Insights are translated into program-level artifacts, including biomarker hypotheses, patient stratification strategies, and evidence packages that support confident go/no-go decisions.
Step 3 — Explainable Network & Mechanistic Inference
The platform builds interpretable tissue-level models that link spatial patterns to underlying biological mechanisms, enabling experts to understand why response, resistance, or progression occurs.
Step 4 — Decision-Grade Outputs 
Insights are translated into program-level artifacts, including biomarker hypotheses, patient stratification strategies, and evidence packages that support confident go/no-go decisions.

Together, these capabilities form a unified system for converting complex tissue biology into actionable program decisions.

Explore how SpaceIQ fits into your
discovery and development programs

Learn how the SpaceIQ™ platform supports tissue analysis, biomarker strategy, and program-scale decision support.

Start a conversation

Subscribe to our Newsletter

* indicates required





Registration

Join us for the Spatial Intelligence Summit. Complimentary and paid registration categories are listed below – hurry, early bird pricing ends on September 30.

We received your request! One of our team members will be in touch as soon as possible.

Submit your Resume

Download Whitepaper

Download Whitepaper

B. Dusty Majumdar, PhD

CHIEF EXECUTIVE OFFICER

Linkedin-in

B. Dusty Majumdar, PhD  is a seasoned leader in Precision Healthcare with more than 20 years of experience in building and successfully launching innovative technologies across oncology, multi-omics, Real-World Evidence (RWE). diagnostic imaging and liquid biopsy platforms leveraging some of the industry’s most advanced AI platforms, genomic and clinical simulations (digital twins), and emerging medical imaging technologies. Dr. Majumdar’s experience includes leading strategy and marketing as the Chief Marketing Officer (CMO) at IBM and multiple commercial and technical leadership roles at GE Healthcare, Exact Sciences and 3M. He has also led the commercial and strategic functions in a range of start-ups in the healthcare/biopharma space over the last few years.  Dr. Majumdar is a widely respected global leader in the healthcare industry and holds a Ph.D. from the University of Texas at Austin and a bachelor’s degree from the Indian Institute of Technology (IIT), Kharagpur.  He has authored several peer-reviewed scientific publications and holds multiple patents.

Joe Camaratta

Sr. VP Business Development

Linkedin-in

Joe Camaratta specializes in medical technology innovation and commercialization, taking products from concept to clinical adoption. He held executive positions for GE Healthcare and Siemens Healthcare and built businesses in medical imaging, cardiology, and oncology. He founded and led two early stage medical technology companies that apply artificial intelligence to improve clinical decision-making.

Joe holds a Master of Science degree in Computer Science from Rutgers University and a Bachelor of Science degree in Computer Science from Drexel University. He currently serves as an advisor to the Entreprenuerial Investing Program of the Crohn’s & Colitis Foundation, and the University Science Center QED Program focused on commercialization of academic innovations

Bruce Campbell, MS

VP Software Engineering

Linkedin-in

Bruce leads the software engineering and quality assurance teams at PredxBio. As the VP of Software Engineering, he is responsible for analytical infrastructure, product development and the commercialization of machine learning, image processing, and computational biology algorithms. Prior to joining PredxBio, Bruce was at IBM and Xylem in global Director of Data Science roles. He has over 20 years of experience in digital pathology algorithms and is highly motivated to deliver care through digital and computational pathology. He has multiple successful FDA 510k device applications, and multiple CLIA certified algorithms deployed in clinical practice.

Bruce holds a BS in Physics and MS in Applied Mathematics from the University of Rochester, an MS in Statistics from North Carolina State University, and is currently pursuing graduate mathematics studies at The Ohio State University. Bruce loves the outdoors. You can find him hiking and rock climbing in Appalachia.